SCHEMBL3498660

SCHEMBL3498660

CC(=O)c1ccc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
S100A4 P26447 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
MAPK1 P28482 2/20 0.44
PKM P14618 2/20 0.44
RAB9A P51151 2/20 0.44
MAPT P10636 2/20 0.41
ABCB1 P08183 1/20 0.41
ABCC1 P33527 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
MAOA P21397 1/20 0.41
ERN1 O75460 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CES2 O00748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30025405 1.00 KDM4E (0.45) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL1890689 0.86 MAPT (0.51) S100A4TRPV1PKMRAB9AMAPT
SCHEMBL17875619 0.85 CES2 (0.53) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL12713755 0.84 S100A4 (0.43) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL15774052 0.84 S100A4 (0.43) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL132963 0.84 GPR35 (0.50) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL15103172 0.82 KDM4E (0.43) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL27745774 0.82 GPR35 (0.49) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL8232986 0.82 DGAT1 (0.53) KDM4ES100A4TRPV1MAPK1PKM
SCHEMBL3911021 0.82 S100A4 (0.44) KDM4ES100A4TRPV1MAPK1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 US disclosed
WO-2025215153-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2025-10-16 WO disclosed
US-20230108114-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-06 US disclosed
US-9884828-B2 Substituted cinnolines as inhibitors of LRRK2 kinase activity IMAGO PHARMACEUTICALS, INC. (US) 2018-02-06 US disclosed
US-9884828-B2 Substituted cinnolines as inhibitors of LRRK2 kinase activity IMAGO PHARMACEUTICALS, INC. (US) 2018-02-06 US disclosed
EP-2615089-B1 Pyrazoloquinoline compounds ASTELLAS PHARMA INC (JP) 2016-04-27 EP disclosed
US-20150284337-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY ELAN PHARMACEUTICALS, INC. (US) 2015-10-08 US disclosed
US-20150284337-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY ELAN PHARMACEUTICALS, INC. (US) 2015-10-08 US disclosed
US-20150284337-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY ELAN PHARMACEUTICALS, INC. (US) 2015-10-08 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed
EP-2615089-A1 PYRAZOLOQUINOLINE COMPOUND Astellas Pharma Inc. (JP) 2013-07-17 EP disclosed
WO-2012162254-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY ELAN PHARMACEUTICALS, INC. (US) 2012-11-29 WO disclosed
WO-2012162254-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY ELAN PHARMACEUTICALS, INC. (US) 2012-11-29 WO disclosed
US-20100160314-A1 Small Molecule Inhibitors of Toll-Like Receptor 9 LIPFORD GRAYSON B 2010-06-24 US disclosed
US-20100160314-A1 Small Molecule Inhibitors of Toll-Like Receptor 9 LIPFORD GRAYSON B 2010-06-24 US disclosed
US-20100160314-A1 Small Molecule Inhibitors of Toll-Like Receptor 9 LIPFORD GRAYSON B 2010-06-24 US disclosed
EP-2081924-A2 SMALL MOLECULE INHIBITORS OF TOLL-LIKE RECEPTOR 9 Coley Pharmaceutical Group, Inc. (US) 2009-07-29 EP disclosed
WO-2008030455-A2 SMALL MOLECULE INHIBITORS OF TOLL-LIKE RECEPTOR 9 COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-03-13 WO disclosed
WO-2008030455-A2 SMALL MOLECULE INHIBITORS OF TOLL-LIKE RECEPTOR 9 COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 KDM4E 306/4885S100A4 4656/4885TRPV1 4750/4885
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND PDE9A, PDE5A, PDE2A KDM4E 1337/4885S100A4 4736/4885TRPV1 670/4885
US-20150284337-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY LRRK2, PARK7, PINK1 KDM4E 1167/4885S100A4 4618/4885TRPV1 2762/4885
US-20230108114-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM4E 57/4885S100A4 3980/4885TRPV1 4772/4885
US-20100160314-A1 Small Molecule Inhibitors of Toll-Like Receptor 9 TLR9, TLR3, TLR1 KDM4E 2032/4885S100A4 1114/4885TRPV1 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.